中国中药(00570.HK) 发盈警，预计6月止六个月溢利净额将较2024年同期下降165%-175%。主要因中药配方颗粒业务受集采业务占比增加、市场竞争加剧等影响，收入规模及盈利能力下降；及中药配方颗粒业务经营业绩不达预期，就业务资产组进一步计提商誉减值。
| 公布日期 | 派息事项 | 派息内容 |
|---|---|---|
| 2025/03/25 | 末期业绩 | 特别股息：港元 0.0830 (约相等于 人民币 0.0766元) |
| 2025/03/25 | 末期业绩 | 股息：港元 0.0035 (约相等于 人民币 0.0032元) |
| 2024/08/28 | 中期业绩 | 无派息 |
| 2024/03/21 | 末期业绩 | 无派息 |
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.